Wen Xiaoli, Xu Gaosi
Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang City, Jiangxi Province, People's Republic of China.
Onco Targets Ther. 2024 Jul 8;17:545-556. doi: 10.2147/OTT.S465679. eCollection 2024.
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described. However, there are a lack of studies analyzing the nephrotoxicity in the anti-cancer BsAbs recipients systematically. In this review, we demonstrate the etiologies, mechanisms, other risk factors and treatment options of kidney injury in the BsAbs recipients to provide a more comprehensive insight into the nephrotoxicity post-BsAbs therapy. Significantly, due to the limited clinical trial data on each subject, we mainly conclude the related etiologies, mechanisms, and risk factors of nephrotoxicity that occur in T-cell-engaging BsAbs recipients. Nephrotoxicity associated with non-T-cell BsAbs may be associated with adverse nephrotoxicity of related monoclonal antibodies to two specific antigens. The aim of this paper is to provide nephrologists and oncologists with theoretical knowledge to provide better medical management for recipients who receive BsAbs, especially T-cell-engaging BsAbs treatment.
近年来，双特异性抗体（BsAbs）正在改变癌症治疗格局，并显著改善了复发或难治性癌症患者的治疗效果。随着越来越多的BsAbs进入临床实践，特定的毒性反应逐渐显现，其中肾脏副作用已有相关报道。然而，目前缺乏系统分析抗癌BsAbs接受者肾毒性的研究。在本综述中，我们阐述了BsAbs接受者肾损伤的病因、机制、其他风险因素及治疗选择，以便更全面地了解BsAbs治疗后的肾毒性。值得注意的是，由于关于每个主题的临床试验数据有限，我们主要总结了参与T细胞的BsAbs接受者中发生肾毒性的相关病因、机制和风险因素。与非T细胞BsAbs相关的肾毒性可能与针对两种特定抗原的相关单克隆抗体的不良肾毒性有关。本文旨在为肾病学家和肿瘤学家提供理论知识，以便为接受BsAbs（尤其是参与T细胞的BsAbs治疗）的患者提供更好的医疗管理。
